Qui som Projectes BRN Seminars Simpòsiums Recercadors DONATE RESPIRATORY MICROBIOME AND COPD EXACERBATIONS RESPIRATORY MICROBIOME AND COPD EXACERBATIONS [content_box icon=”bookmark-o” title=”Research team”] Dr. Oriol Sibila (PRINCIPAL INVESTIGATOR) Institut d’Investigació Biomèdica Sant Pau Dra. Rosa Faner (PRINCIPAL INVESTIGATOR) Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS) Dra. Marian Garcia-Nuñez Institut Universitari Parc Taulí Dr. Jordi Dorca Institut d’Investigació Biomèdica de Bellvitge Dra. Judit Villar Instituto del Hospital del Mar de Investigaciones Médicas (IMIM) Dra. Alicia Marin Fundació Institut d’Investigació en Ciéncies de la Salut Germans Trias i Pujol Dr. Luis Fernando Casas Instituto Institut d’Investigació Biomèdica de Lleida Dr. Toni Gabaldón Centre de Regulació Genòmica (CRG) [/content_box] [content_box icon=”bookmark-o” title=”Abstract”] The objective of this coordinated, multicenter and translational project is to test the hypothesis that the pulmonary microbiome is different in patients with Chronic Obstructive Pulmonary Disease (COPD) with frequent exacerbations (FE) compared with those COPD patients with no exacerbations (NE). Microbiome differences will be assessed in different pulmonary and extra-pulmonary (gut) compartments, and their relationship with the local and systemic immune response will be investigated. Likewise, the spatial reproducibility of the pulmonary microbiome and the potential translation of these findings to sputum as a clinically useful tool will be assessed. Methodology: 150 individuals will be recruited (50 COPD patients with FE, 50 COPD patients with NE and 50 healthy non-smokers). Bronchoalveolar lavage (BAL) in different lung regions, Tracheal Aspirate (TA), sputum, nasal and oral swabs, peripherals blood and fecal samples will be collected. The microbiome sequencing and analysis will be performed using next-generation sequencing of 16S rRNA. The integration of the results will be performed using network medicine methodologies. In the supernatant of sputum and BAL, levels of mucins, antimicrobial peptides and inflammatory cytokines will be determined using ELISA techniques. Expression of TLR in lung leukocytes will be determined using sputum flow cytometry. Systemic immune response will be assessed by a number of inflammatory markers, bacterial translocation products and mRNA expression patterns in blood. The results of this project will help to understand the pathogenesis of COPD and its exacerbations with the final aim to identify new therapeutic targets. [/content_box] [content_box icon=”bookmark-o” title=”Financial suport”] [/content_box] Copyright © 2021 Fundació Barcelona Respiratory Network C/ Bruc, 65, 4t, 3a, 08009 Barcelona NIF: G65893091 Inscrita en el Registre de Fundacions de la Generalitat de Catalunya. Nº 2.791. Telf. 93 633 89 15 / info@brn.cat / www.brn.cat Choose your language